Analysts think FOLD stock price could increase by 3%
Feb 07, 2026, 12:26 PM
0.28%
What does FOLD do
Amicus Therapeutics, a Philadelphia-based biotechnology company with 517 employees, went public in 2007 and markets Galafold for Fabry disease and Pombiliti + Opfolda for late-onset Pompe disease. Galafold stabilizes alpha-Gal A enzyme, while Pombiliti + Opfolda enhances enzyme uptake in relevant tissues.
9 analysts think FOLD stock price will increase by 3.50%. The current median analyst target is $14.79 compared to a current stock price of $14.29. The lowest analysts target is $14.14 and the highest analyst target is $23.10.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.